Michelle M. Lilly

5.7k total citations
103 papers, 4.4k citations indexed

About

Michelle M. Lilly is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michelle M. Lilly has authored 103 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 35 papers in Molecular Biology and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michelle M. Lilly's work include Prostate Cancer Treatment and Research (29 papers), Cancer Mechanisms and Therapy (17 papers) and Cancer Genomics and Diagnostics (16 papers). Michelle M. Lilly is often cited by papers focused on Prostate Cancer Treatment and Research (29 papers), Cancer Mechanisms and Therapy (17 papers) and Cancer Genomics and Diagnostics (16 papers). Michelle M. Lilly collaborates with scholars based in United States, China and Singapore. Michelle M. Lilly's co-authors include Andrew S. Kraft, Marina Zemskova, Päivi J. Koskinen, Jouko Sandholm, Sheldon L. Holder, Katriina Peltola, Harri Mankonen, Matthew R. Janes, I Brezovich and Eva Sahakian and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Michelle M. Lilly

100 papers receiving 4.3k citations

Peers

Countries citing papers authored by Michelle M. Lilly

Since Specialization

Citations

This map shows the geographic impact of Michelle M. Lilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle M. Lilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle M. Lilly more than expected).

Fields of papers citing papers by Michelle M. Lilly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle M. Lilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle M. Lilly. The network helps show where Michelle M. Lilly may publish in the future.

Co-authorship network of co-authors of Michelle M. Lilly

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle M. Lilly. A scholar is included among the top collaborators of Michelle M. Lilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle M. Lilly. Michelle M. Lilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression 2025 ·Cancer Research ·Natalia V. Oleinik, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Zdzisław M. Szulc, Elizabeth G. Hill, Alexander V. Alekseyenko, Hüseyin Çimen, (unknown), Christina Voelkel‐Johnson, Michelle M. Lilly, John J. Lemasters, Norma Frizzell, Xue‐Zhong Yu, Shikhar Mehrotra, Besim Öğretmen	1
2	Racial Distribution of Neighborhood-Level Social Deprivation in a Retrospective Cohort of Prostate Cancer Survivors 2022 ·SHILAP Revista de lepidopterología ·Oluwole Adeyemi Babatunde, John L. Pearce, Melanie Jefferson, Lewis J. Frey, Peggi M. Angel, Richard R. Drake, Caitlin G. Allen, Michelle M. Lilly, Stephen J. Savage, Chanita Hughes Halbert	4
3	Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals 2022 ·Journal of Immunology Research ·Xu Wang, Zejun Zhou, David P. Turner, Michelle M. Lilly, (unknown), Wei Jiang	8
4	Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies 2021 ·OncoImmunology ·Hannah M. Knochelmann, (unknown), Megan M. Wyatt, Aubrey S. Smith, (unknown), Connor J. Dwyer, Michael Bobian, Guillermo O. Rangel Rivera, (unknown), Michelle M. Lilly, Martin J. Romeo, Cynthia Timmers, Mark P. Rubinstein, David M. Neskey, Chrystal M. Paulos	5
5	Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β 2020 ·Science Translational Medicine ·Alessandra Metelli, Bill X. Wu, Brian Riesenberg, Silvia Guglietta, John D. Huck, Catherine M. Mills, Anqi Li, Saleh Rachidi, Carsten Krieg, Mark P. Rubinstein, D.T. Gewirth, Shaoli Sun, Michelle M. Lilly, Amy H. Wahlquist, David P. Carbone, Yiping Yang, Bei Liu, Zihai Li	91
6	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer 2020 ·Cancer Treatment and Research Communications ·(unknown), Alex Niu, Michelle M. Lilly, Andrew W. Hahn, Roberto Nussenzveig, Elisa M. Ledet, (unknown), (unknown), Brian Lewis, Jodi Lyn Layton, Neeraj Agarwal, Oliver Sartor, Pedro C. Barata	1
7	Social and clinical determinants of physical activity in prostate cancer survivors 2020 ·Supportive Care in Cancer ·Chanita Hughes Halbert, Melanie Jefferson, Richard R. Drake, Michelle M. Lilly, Stephen J. Savage, Georges J. Nahhas, (unknown), (unknown), (unknown)	4
8	Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer 2019 ·Cancer ·Guru Sonpavde, Neeraj Agarwal, Gregory R. Pond, Rebecca J. Nagy, Roberto Nussenzveig, Andrew W. Hahn, Oliver Sartor, Theodore Stewart Gourdin, Lakshminarayanan Nandagopal, Elisa M. Ledet, Gurudatta Naik, Andrew J. Armstrong, Jue Wang, Mehmet Asım Bilen, Shilpa Gupta, Petros Grivas, Sumanta K. Pal, Richard B. Lanman, AmirAli Talasaz, Michelle M. Lilly	41
9	The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer 2018 ·Frontiers in Immunology ·(unknown), Michelle M. Lilly, Wei Jiang	51
10	Discordance in perceived risk and epidemiological outcomes of prostate cancer among African American men 2017 ·Preventive Medicine Reports ·(unknown), Melanie Jefferson, (unknown), Ernestine Delmoor, Jerry Johnson, Sebastiano Gattoni‐Celli, Stephen J. Savage, Michelle M. Lilly, Sandip M. Prasad, Rick A. Kittles, Chanita Hughes Halbert	5
11	Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue 2017 ·Journal of Hematology & Oncology ·Gang Liu, Jinyu Zhang, Lewis J. Frey, Gang Xiao, Kongming Wu, Qian Liu, Michelle M. Lilly, Jennifer D. Wu	26
12	p53-Dependent Induction of Prostate Cancer Cell Senescence by the PIM1 Protein Kinase 2010 ·Molecular Cancer Research ·Marina Zemskova, Michelle M. Lilly, Ying-Wei Lin, Jin H. Song, Andrew S. Kraft	34
13	Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells 2009 ·Molecular Cancer Therapeutics ·Zanna Beharry, Marina Zemskova, Sandeep Mahajan, Fengxue Zhang, Jian Ma, Zuping Xia, Michelle M. Lilly, Charles D. Smith, Andrew S. Kraft	83
14	PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells 2009 ·Cancer Biology & Therapy ·Fengxue Zhang, Zanna Beharry, Thurl E. Harris, Michelle M. Lilly, Charles D. Smith, Sandeep Mahajan, Andrew S. Kraft	108
15	Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75 2009 ·Molecular Cancer ·Melanie Mediavilla-Varela, Fabio J. Pacheco, Frankis Almaguel, (unknown), Eva Sahakian, Tracy R. Daniels‐Wells, Lai Sum Leoh, Amelia Padilla, Nathan R. Wall, Michelle M. Lilly, Marino De León, Carlos A. Casiano	101
16	The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells 2008 ·Journal of Biological Chemistry ·Marina Zemskova, Eva Sahakian, (unknown), Michelle M. Lilly	110
17	Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase 2007 ·Molecular Cancer Therapeutics ·Sheldon L. Holder, Marina Zemskova, Chao Zhang, M. Tabrizizad, Ryan Bremer, Jonathan W. Neidigh, Michelle M. Lilly	158
18	Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser¹¹² gatekeeper site 2004 ·FEBS Letters ·(unknown), Jouko Sandholm, Katriina Peltola, Harri Mankonen, Michelle M. Lilly, Päivi J. Koskinen	276
19	Pentoxifylline inhibits tumor necrosis factor-α-mediated cytotoxicity and cytostasis in L929 murine fibrosarcoma cells 1994 ·International Journal of Immunopharmacology ·(unknown), Bruce Montgomery, William L. Stahl, Carole Crittenden, Mary A. Valentine, David Thorning, David Andrews, Michelle M. Lilly	17
20	Loss of high-energy phosphate following hyperthermia demonstrated by in vivo 31P-nuclear magnetic resonance spectroscopy. 1984 ·PubMed ·Michelle M. Lilly, Thian C. Ng, William T. Evanochko, Charles R. Katholi, (unknown), Gabriel A. Elgavish, John Durant, Raymond N. Hiramoto, Vithal K. Ghanta, Jerry D. Glickson	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact